What are the Australian guidelines for managing an acute asthma exacerbation in adults, including discharge criteria and indications for referral versus self‑management?

Acute Asthma Exacerbation Management in Australia

Initial Assessment and Severity Classification

Classify severity immediately using FEV₁ or peak expiratory flow (PEF) as the primary determinant, combined with clinical signs including respiratory rate, pulse, oxygen saturation, ability to speak in sentences, and accessory muscle use 1, 2.

Severity Categories:

• Mild: PEF ≥70% predicted, dyspnea only with activity
• Moderate: PEF 40-69% predicted, dyspnea interferes with usual activity
• Severe: PEF <40% predicted, dyspnea at rest, interferes with conversation
• Life-threatening: PEF <25% predicted, too dyspneic to speak, perspiring 2

High-Risk Patients Requiring Extra Vigilance:

Identify patients with risk factors for asthma-related death 1:

• Previous severe exacerbation (intubation or ICU admission)
• ≥2 hospitalizations for asthma in past year
• ≥3 ED visits for asthma in past year
• Hospitalization or ED visit in past month
• Using >2 canisters of short-acting beta-agonist per month
• Cardiovascular disease, chronic lung disease, or psychiatric comorbidities
• Low socioeconomic status, illicit drug use

Emergency Department Treatment Protocol

Immediate Management:

1. Oxygen: Maintain SaO₂ ≥92-94%
2. Short-acting beta-agonist (SABA): Repeat every 20 minutes for first hour
3. Oral corticosteroids: Administer early in all moderate-to-severe cases 1, 2

Reassess at 1 Hour:

Repeated lung function measures (FEV₁ or PEF) at 1 hour are the strongest single predictor of hospitalization in adults 2. Pulse oximetry <92-94% after 1 hour predicts need for hospitalization.

Adjunctive Therapies for Severe/Unresponsive Cases:

• Ipratropium bromide (short-acting muscarinic antagonist): Reduces hospitalizations 3
• Intravenous magnesium sulfate: Consider if FEV₁ or PEF remains <40% predicted after initial treatments 2, 3
• Heliox: Consider in severe exacerbations unresponsive to initial therapy 2

Discharge Criteria

Discharge is appropriate when patients achieve FEV₁ or PEF 60-80% of predicted values with improvement in symptoms 3.

Additional discharge requirements:

• Stable on 3-4 hourly bronchodilator therapy
• SaO₂ ≥92% on room air
• Able to walk without dyspnea
• Patient/family confident in home management

Critical Pitfall:

Do NOT discharge patients who continue to meet moderate or severe criteria after 1-2 hours of treatment—they have >84% chance of requiring hospitalization 2.

Mandatory Discharge Planning

All discharged patients must receive 2:

1. Oral corticosteroids: 5-7 day course (appropriate dosing in only 63% of cases per recent audit 4)
2. Written asthma action plan: Review and update
3. Inhaler technique review: Only 42% of patients had this checked in past year 5
4. Follow-up within 1-4 weeks: Essential to review action plan, adherence, environmental control
5. Consider initiating or stepping up inhaled corticosteroids (ICS): Critical for preventing future exacerbations
6. Telephone contact encouraged within 3-5 days post-discharge 2

When to Refer/Not Treat Yourself

Immediate Transfer to Higher-Level Care Required:

• Life-threatening exacerbation: PEF <25%, unable to speak, drowsiness (indicates impending respiratory failure) 2
• Severe exacerbation not responding to initial treatment: FEV₁/PEF remains <40% after 1 hour of aggressive therapy
• Deteriorating mental status: Drowsiness, confusion, agitation
• Persistent hypoxemia: SaO₂ <92% despite oxygen therapy
• Pneumothorax or pneumomediastinum suspected
• Inability to provide continuous monitoring and frequent treatments

Admit to Hospital:

• Patients meeting moderate-to-severe criteria after 1-2 hours of ED treatment 2
• Inadequate response to bronchodilators (FEV₁/PEF <60% predicted)
• High-risk patients even with moderate exacerbations
• Lack of social support or inability to access follow-up care

Specialist Referral Indications (Outpatient):

• Recurrent exacerbations despite appropriate therapy
• Poor symptom control (ACT <20)
• Patients requiring step 4-5 therapy
• Diagnostic uncertainty
• Consideration for biologic therapy

Critical Australian Context

Recent 2021 Australian data reveals alarming trends 5:

• Only 48% have well-controlled asthma (ACT ≥20)
• 38.1% have uncontrolled symptoms with little/no ICS use
• 56.3% overuse SABA (≥3 inhalers/year)
• Urgent healthcare utilization increased to 37.9%

This underscores the urgent need for aggressive discharge planning, ICS initiation, and close follow-up to prevent the revolving door of ED visits.